Back to top
more

Quest Diagnostics (DGX)

(Real Time Quote from BATS)

$173.66 USD

173.66
350,231

+1.22 (0.71%)

Updated Aug 5, 2025 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can Quest Diagnostics (DGX) Pull a Surprise in Q2 Earnings?

by Zacks Equity Research

Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.

    Zacks Equity Research

    3 Excellent Value Picks Amid Political Grind in MedTech

    by Zacks Equity Research

    While the revised American Health Care Act now only needs the Senate's nod, the scenario is getting increasingly challenging for the Medical Device Space.

      Zacks Equity Research

      Here's Why You Can Buy Quest Diagnostics Stock Right Now

      by Zacks Equity Research

      Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.

        Zacks Equity Research

        Quest Diagnostics to Buy Outreach Lab Service in Cape Cod

        by Zacks Equity Research

        Quest Diagnostics Inc. (DGX) recently teamed up with Cape Cod Healthcare (CCHC) to obtain its outreach laboratory service business.

          Zacks Equity Research

          Quest Diagnostics Enhances Blueprint for Athletes Service

          by Zacks Equity Research

          Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.

            Zacks Equity Research

            Why Quest Diagnostics (DGX) is a Suitable Pick for Investors

            by Zacks Equity Research

            Madison, NJ-based Quest Diagnostics, Inc. (DGX), a provider of commercial laboratory services, has been on a growth trajectory of late.

              Zacks Equity Research

              Why You Should Avoid Envision Healthcare (EVHC) Stock Now

              by Zacks Equity Research

              Investors' pessimism about Envision Healthcare (EVHC) has stemmed from the decline in 2017 earnings guidance, following first-quarter results.

                Zacks Equity Research

                Quest Diagnostics to Buy 2 Labs, Grow in Oncology Space

                by Zacks Equity Research

                Quest Diagnostics (DGX) recently announced agreements to acquire two laboratory businesses in Lewisville, Texas, namely Med Fusion and Clear Point.

                  Zacks Equity Research

                  Quest Diagnostics (DGX) Up 1.8% Since Earnings Report: Can It Continue?

                  by Zacks Equity Research

                  Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Zacks Equity Research

                    Quest Diagnostics Poised on Solid Q1 Results Despite Woes

                    by Zacks Equity Research

                    On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.

                      Zacks Equity Research

                      Top Ranked Momentum Stocks to Buy for April 24th

                      by Zacks Equity Research

                      Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 24th:

                        Zacks Equity Research

                        Quest Diagnostics (DGX) Looks Good: Stock Moves 6% Higher

                        by Zacks Equity Research

                        Quest Diagnostics Incorporated (DGX) shares rose to 6% in the last trading session.

                          Zacks Equity Research

                          Quest Diagnostics (DGX) Tops Q1 Earnings & Sales Estimates

                          by Zacks Equity Research

                          Currently, Quest Diagnostics has a Zacks Rank #2 (Buy) but that could change following its strong first quarter 2017 earnings report which has just released.

                            Zacks Equity Research

                            Should You Sell Quest Diagnostics (DGX) Before Earnings?

                            by Zacks Equity Research

                            Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                              Zacks Equity Research

                              Will Quest Diagnostics (DGX) Pull a Surprise in Q1 Earnings?

                              by Zacks Equity Research

                              Quest Diagnostics Inc. (DGX) is scheduled to report first-quarter 2017 earnings results before the opening bell on Apr 20.

                                Zacks Equity Research

                                Quest Diagnostics Partners with Veracyte for Cancer Testing

                                by Zacks Equity Research

                                Quest Diagnostics Incorporated (DGX) has recently entered into an agreement with genomic diagnostics company Veracyte, Inc. (VCYT), for the extended access of Afirma Gene Expression Classifier (GEC).

                                  Zacks Equity Research

                                  Quest Diagnostics (DGX): Tops Q4 Earnings, Sales in Line

                                  by Zacks Equity Research

                                  Quest Diagnostics (DGX) earnings per share has beaten Zacks Consensus Estimate while sales were in line with the mark.

                                    Zacks Equity Research

                                    Should You Buy Quest Diagnostics (DGX) Ahead of Earnings?

                                    by Zacks Equity Research

                                    Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                      Zacks Equity Research

                                      IBM Corp (IBM) Beats on Q4 Earnings; FY17 View Positive

                                      by Zacks Equity Research

                                      International Business Machines Corp (IBM) reported fourth-quarter 2016 non-GAAP earnings of $5.01 per share, which increased 3.5% from the year-ago quarter.

                                        Zacks Equity Research

                                        Quest Diagnostics (DGX) Launches HBV Quantitative Test

                                        by Zacks Equity Research

                                        Quest Diagnostics Inc. (DGX), a global provider of diagnostic information services, recently rolled out Hepatitis B Virus (HBV) Quantitative Test.

                                          Zacks Equity Research

                                          Quest Diagnostics (DGX) Q4 Earnings: What Lies in Store?

                                          by Zacks Equity Research

                                          Quest Diagnostics Inc. (DGX) is scheduled to report fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 26, 2017.

                                            Zacks Equity Research

                                            Anthem Extends Alliance with Inovalon, Boosts Customer Value

                                            by Zacks Equity Research

                                            Leading U.S.-based Health Maintenance Organization (HMO), Anthem Inc. (ANTM), recently declared a multi-year extension of its partnership with Inovalon Holdings, Inc. (INOV).

                                              Zacks Equity Research

                                              Quest Diagnostics: Strong Q3, Strategic Initiatives Add Value

                                              by Zacks Equity Research

                                              On Dec 27, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).

                                                Sheraz Mian headshot

                                                New Research Reports on NFLX, AXP, GM & Others

                                                by Sheraz Mian

                                                Today's must-read reports are for Netflix (NFLX), American Express (AXP) and General Motors (GM).